Objectives: (1) To examine U.S. national trends in the use of concomitant pharmacotherapy with the stimulant class of psychotropic drugs in youth; and (2) to present these trends in the context of (a) extant safety and efficacy data, and (b) overall trends in concomitant pharmacotherapy with psychotropic drugs for youth.
Methods: Prescribing data for youths under age 18 years from National Ambulatory Medical Surveys from 1993 to 1998 were analyzed. The visits were categorized into monotherapy (only one psychotropic prescribed) and concomitant pharmacotherapy (>1 psychotropic prescribed). The proportions of these groups were computed as a percentage of all visits during which a psychotropic medication was prescribed. Differences in proportions between surveys were analyzed to determine trends.
Results: Between 1993-94 and 1997-98, the proportions of visits for concomitant pharmacotherapy in association with the stimulant class increased nearly five-fold. This increase paralleled an overall increase in the proportion of visits involving prescription of more than one psychotropic medication among youth.
Conclusions: The growth in concomitant pharmacotherapy with the stimulants class has out-paced the increase in safety/efficacy data to inform the use of this practice, resulting in a mismatch between trends in prescribing and growth in knowledge. A simultaneous trend of note is the overall increase in the use of concomitant pharmacotherapy with all psychotropic drugs in youth. Controlled trials are particularly needed to support commonly used combinations of stimulants with antidepressants in youth. In the absence of definitive data, clinical guidelines based on expert consensus and limited data are available and are useful.
Get full access to this article
View all access options for this article.
References
1.
American Academy of Pediatrics, Subcommittee on ADHD and Committee on Quality Improvement (2001). Clinical practice guidelines: Treatment of the school-aged children with Attention-Deficit/Hyperactivity Disorder. Pediatrics, 108, 1033-1044.
2.
Barret, J., Meehan, O., & Fahy, T. (1996). SSRI and sympathomimetic interaction. British Journal of Psychiatry, 168, 253 (letter).
3.
Bhatara, V. S., Feil, M., Hoagwood, K., Vitiello, B., & Zima, B. (2002). Datapoints: Trends in combined pharmacotherapy with stimulants for children. Psychiatric Services, 53, 244.
4.
Bhatara, V. S., Kallepalli, B., Misra, L., & Awadallah, S. (1996). A possible clonidine-trazodone-dextroamphetamine interaction in a 12-year-old boy. Journal of Child and Adolescent Psychopharmacology, 6, 203-209.
5.
Bhatara, V. S., Magnus, R. D., Paul, K. L., & Preskorn, S. H. (1998). Serotonin syndrome induced by venlafaxine and fluoxetine: A case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Annals of Pharmacotherapy, 32, 432-436.
6.
Bussing, R., & Levin, G. M. (1993). Methamphetamine and fluoxetine treatment of a child with attention deficit hyperactivity disorder and obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology, 3, 53-58.
7.
Carlson, G. A., Rapport, M. D., Kelly, K., & Pataki, C. (1995). Methylphenidate and desipramine in hospitalized children with comorbid behavior and mood disorders: Separate and combined effects on behavior and mood. Journal of Child and Adolescent Psychopharmacology, 5, 191-204.
8.
Cohen, L. G., Prince, J., Biederman, J., Wilens, T., Farone, S. V., Whitt, S., et al., (1999). Absence of effects of stimulants on the pharmacokinetics of desipramine in children. Pharmacotherapy, 19, 746-752.
9.
Connor, D. F., Barkley, R. A., & Davis, H. (2000). A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clinical Pediatrics, 39, 15-25.
10.
DeVane, C. L., Markowitz, J., Carson, S., Boulton, D., Gill, H. S., Nahas, Z., et al. (2000). Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers. Journal of Clinical Psychopharmacology, 20, 347-349.
11.
Findling, R. L. (1996). Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: A case series. Journal of Child and Adolescent Psychopharmacology, 6, 165-175.
12.
Flemenbaum, A. (1972). Hypertensive episodes after adding methylphenidate (Ritalin) to tricyclic antidepressants. Psychosomatics, 13, 265-268.
13.
Gammon, G. D., & Brown, T. E. (1993). Fluoxetine and methylphenidate in combination for treatment of attention deficit and comorbid depressive disorder. Journal of Child and Adolescent Psychopharmacology, 3, 1-10.
14.
Greenhill, L. L., Pliszka, S., Ducan, M. K., Bernet, W., Arnold, V., Beitchman, J., et al. (2002). Practice parameters for the use of stimulants medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry, 41 (Suppl. 2) 26S-49S.
15.
Guyatt, G. H., Haynes, R. B., Jaeschke, R. Z., Cook, D. J., Green, L., Naylor, C. D., et al. (2000). User’s guide to medical literature XXV. Evidence-based medicine: Principles for applying the user’s guide to patient care. Journal of the American Medical Association, 284, 1290-1296.
16.
Hazell, P. L., & Stuart, J. E. (2003). A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 886-894.
17.
Hoagwood, K., Jensen, P. S., Feil, M., Vitiello, B., & Bhatara, V. S. (2000). Management of stimulants and other psychotropics in pediatric practice. Journal of Developmental and Behavioral Pediatrics, 21, 322-331.
18.
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J., Gavaghan, D. J., et al. (1996). Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 17, 1-12.
19.
Jensen, P. S., Bhatara, V. S., Vitiello, B., Hoagwood, K., Feil, M., & Burke, L. B. (1999). Psychoactive medication prescribing practices for U. S. children: Gaps between research and clinical practice. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 557-565.
20.
Lavretsky, H., Kim, M. D., Kumar, A., & Reynolds, C. F. (2003). Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: An open trial. Journal of Clinical Psychiatry, 64, 1410-1414.
21.
Markowitz, J. S., & Patrick, K. S. (2001). Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clinical Pharmacokinetics, 40, 753-772.
22.
MTA Cooperative Group (1999). A 14-month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder. The MTA Group multimodal treatment study of children with ADHD. Archives of General Psychiatry, 56, 1073-1086.
23.
Nass, R., & Bressman, S. (2002). Attention deficit hyperactivity disorder and Tourette syndrome: What’s the best treatment?Neurology, 58, 513-514.
24.
National Center for Health Statistics (1993-1999). National Ambulatory Medical Survey. Retrieved June 2nd, 2000 from www.cdc.gov/nchs/about/major/ahcd/sampnam.htm.
25.
Olfson, M., Marcus, S. C., Weissman, M. M., & Jensen, P. S. (2002). National trends in the use of psychotropic medications by children. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 514-521.
26.
Parraga, H. C., Kelly, D., Parraga, M., Cochran, M., & Maxim, L. (1994). Combined psychostimulant and tricyclic antidepressant treatment of Tourette’s syndrome and comorbid disorders in children. Journal of Child and Adolescent Psychopharmacology, 4, 113-122.
27.
Pliszka, S. R. (2003). Psychiatric comorbidities in children with attention deficit hyperactivity disorder: Implications for management. Paediatric Drugs, 5, 741-750.
28.
Pliszka, S. R., Greenhill, L. L., Crismon, M. L., Sedillo, A., Carlson, C., Conners, C. K., et al. (2000a). The Texas children’s medication algorithm project: Report of the Texas consensus conference panel on medication treatment of childhood Attention-Deficit/Hyperactivity Disorder. Part I. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 908-919.
29.
Pliszka, S. R., Greenhill, L. L., Crismon, M. L., Sedillo, A., Carlson, C., Conners, C. K., et al. (2000b). The Texas children’s medication algorithm project. Report of the Texas consensus conference panel: Medication treatment of childhood attention deficit/hyperactivity disorder. Part II: Tactics. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 920-927.
30.
Prince, J. B., Wilens, T. E., Biederman, J., Spencer, T. J., & Wozniak, J. R. (1996). Clonidine for sleep disturbance associated with attention-deficit hyperactivity disorder: A systematic chart review of 62 cases. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 599-605.
31.
Regino, R., Barren, M., Connor, D. F., & Swanson, J. M. (2000). Patterns of use of clonidine alone and in combination with methylphenidate. In L. Greenhill & B. Osman (Eds.), Ritalin: Theory and practice, 2nd ed. pp. 401-400. New York: Mary Ann Liebert Publishers.
32.
Research Triangle Institute (2003). SUDAAN v8.0. Research Triangle Park, NC: Research Triangle Institute.
33.
Rushton, J. L., & Whitmore, J. T. (2001). Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends:1992 to 1998. Archives of Pediatric and Adolescent Medicine, 155, 560-565.
34.
Safer, D. J., Zito, J. M., & dosReis, S. (2003). Concomitant psychotropic medication for youths. American Journal of Psychiatry, 160, 438-449.
35.
Tourette’s Syndrome Study Group (2002). Treatment of ADHD in children with tics: A randomized controlled trial. Neurology, 58, 527-536.
36.
Varley, C. K. (2000). Sudden death of a child treated with imipramine. Case study. Journal of Child and Adolescent Psychopharmacology, 10, 321-325.
37.
Wilens, T. E., Spencer, T. E., Swanson, J. M., Connor, D. F., & Cantwell, D. (1999). Combining methylphenidate and clonidine: A clinically sound medication option. Journal of American Academy of Child and Adolescent Psychiatry, 38, 614-619.
38.
Wolraich, M. (2002). Current assessment and treatment practices in ADHD. In P. S. Jensen & J. R. Cooper (Eds.), Attention-Deficit/Hyperactivity Disorder: State of the Science: Best practices (pp. 23/1-23/10). Kingston NJ: Civic Research Institute.
39.
Woodwell, D. A. (1997). National Ambulatory Medical Care Survey: 1995 summary. Advance Data, 286, 1-25.
40.
Woodwell, D. A. (1999). National Ambulatory Medical Care Survey: 1997 summary. Advance Data, 305, 1-28.
41.
Woodwell, D. A. (2000), National Ambulatory Medical Care Survey: 1998 summary. Advance Data, 315, 1-26.
42.
Woodwell, D. A., & Shappert, S. M. (1995). National Ambulatory Medical Care Survey: 1993 summary. Advance Data, 270, 1-20.
43.
Woolston, J. L. (1999). Combined pharmacotherapy: Pitfalls of treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 1455-1457.
44.
Zito, J. M., & Safer, D. J. (1997). Sources of data for pharmacoepidemiological studies of child and adolescent psychiatric disorders. Journal of Child and Adolescent Psychopharmacology, 7, 237-253.
45.
Zito, J. M., Safer, D. J., dosReis, S., Gardner, J. F., Magder, L., Soeken, K., et al. (2003). Psychotropic practice patterns for youth: A 10-year perspective. Archives of Pediatric and Adolescent Medicine, 157, 17-25.
46.
Zito, J. M., Safer, D. J., dosReis, S., Gardner, J. F., Soeken, K., Boles, M., et al. (2002). Rising prevalence of antidepressants among US youths. Pediatrics, 109, 721-727.
47.
Zito, J. M., Safer, D. J., dosReis, S., Magder, L., Gardner, J. F., & Zarin, D. A. (1999). Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder. Archives of Pediatric and Adolescent Medicine, 153, 1257-1263.
48.
Zito, J. M., Safer, D. J., Riddle, M. A., Johnson, R. E., Speedie, S. M., & Fox, M. (1998). Prevalence variations in psychotropic treatment of children. Journal of Child and Adolescent Psychopharmacology, 8, 99-105.
